Alkermes begins Phase II trial of ALKS 2680 for narcolepsy type 1

Alkermes has commenced the Vibrance-1 Phase II clinical trial to evaluate ALKS 2680 in patients with narcolepsy type 1 (NT1).

ALKS 2680 is an investigational oral orexin 2 receptor (OX2R) agonist intended as a once-daily treatment for the chronic neurological disorder known for causing excessive daytime sleepiness.